Combined, our chemical inhibitor screening, gene knockdown and bioinformatic analyses consistently indicate a collaborative role of the integrin-FAK pathway and BRD4/Myc-linked epigenetic network in controlling tumor cell variability in NSCLC, regardless state of KRAS or EGFR. The gene discussed is BRD4; the disease is non-small cell lung carcinoma.